FDA Approves New Drug for Metastatic Pancreatic Cancer

The FDA granted expedited approval to daraxonrasib, a first-in-class targeted therapy for metastatic pancreatic cancer. The drug blocks the mutated KRAS protein found in over 90% of pancreatic cancer cases.

🐿️ This approval finally addresses the KRAS mutation, a target that had been considered undruggable for decades, offering new hope for a notoriously hard-to-treat cancer.